Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating income | — | -$138K | -$1.01M | -$20.6M | -$23.5M |
| Net income | — | $381K | -$12.7M | -$21.1M | -$24.8M |
| EPS (diluted) | — | $0.12 | -$0.19 | -$0.31 | -$0.34 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | — | -$48.0K | -$601K | $126K | -$5.49M |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | $112.00 | $3.92M |
| Total assets | $126K | $68.2M | $47.7M | $84.4M | $101M |
| Total liabilities | — | — | $22.2M | $38.2M | $56.1M |
| Shareholders' equity | -$10.1K | $36.3M | $25.5M | $46.1M | $44.9M |
| Retained earnings | -$10.1K | $345K | -$18.1M | -$39.3M | -$64.0M |
| Shares (wtd avg diluted) | 2.42M | 1.34M | 67.5M | 68.1M | 73.3M |
Every figure is extracted from CITIUS ONCOLOGY, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.